Literature DB >> 11914599

ARHI/NOEY2 inactivation may be important in breast tumor pathogenesis.

Hisashi Hisatomi1, Kumi Nagao, Kazuyuki Wakita, Norio Kohno.   

Abstract

Allelic loss frequently occurs on the short arm of chromosome 1 in human breast carcinoma, suggesting that the ARHI/NOEY2 gene, an imprinted putative tumor suppressor gene, is involved in the pathogenesis of the tumor entity. To clarify the clinical importance of ARHI/NOEY2 mRNA in breast cancer, we studied whether ARHI/NOEY2 inactivation might contribute to tumors arising in the breast. An ARHI/NOEY2 message was detected by real-time PCR analysis in all noncancerous breast tissues, but was not detected in 2 of 26 breast cancer tissue samples. In 10 of 26 breast cancer tissue samples ARHI/NOEY2 mRNA was substantially reduced. ARHI/NOEY2 expression was lost or markedly reduced in 12 of 26 (46.15%) breast cancer tissue samples. In summary, we conclude that decreased ARHI/NOEY2 mRNA expression may play an important role in the pathogenesis of breast cancer. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11914599     DOI: 10.1159/000048259

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  8 in total

1.  Over-expression of ARHI decreases tumor growth, migration, and invasion in human glioma.

Authors:  Jing Chen; Songsheng Shi; Weizhong Yang; Chunmei Chen
Journal:  Med Oncol       Date:  2014-01-24       Impact factor: 3.064

2.  Somatic Mutation of ARHI Gene in Hepatocellular Carcinomas.

Authors:  Chang Jae Kim; Jung Woo Shin; Seok Won Jung; Bo Ryung Park; Neung Hwa Park
Journal:  Pathol Oncol Res       Date:  2015-07-05       Impact factor: 3.201

3.  The tumor suppressor DiRas3 forms a complex with H-Ras and C-RAF proteins and regulates localization, dimerization, and kinase activity of C-RAF.

Authors:  Angela Baljuls; Matthias Beck; Ayla Oenel; Armin Robubi; Ruth Kroschewski; Mirko Hekman; Thomas Rudel; Ulf R Rapp
Journal:  J Biol Chem       Date:  2012-05-17       Impact factor: 5.157

4.  DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells.

Authors:  Zhen Lu; Maria T Baquero; Hailing Yang; Maojie Yang; Albert S Reger; Choel Kim; Douglas A Levine; Charlotte H Clarke; Warren S-L Liao; Robert C Bast
Journal:  Autophagy       Date:  2014-06       Impact factor: 16.016

5.  ARHI: A new target of galactose toxicity in Classic Galactosemia.

Authors:  K Lai; M Tang; X Yin; H Klapper; K Wierenga; Lj Elsas
Journal:  Biosci Hypotheses       Date:  2008

6.  Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.

Authors:  Tianjiao Lyu; Nan Jia; Jieyu Wang; Xiaohui Yan; Yinhua Yu; Zhen Lu; Robert C Bast; Keqin Hua; Weiwei Feng
Journal:  Epigenetics       Date:  2013-10-17       Impact factor: 4.528

7.  ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.

Authors:  M N Washington; G Suh; A F Orozco; M N Sutton; H Yang; Y Wang; W Mao; S Millward; A Ornelas; N Atkinson; W Liao; R C Bast; Z Lu
Journal:  Cell Death Dis       Date:  2015-08-06       Impact factor: 8.469

8.  JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.

Authors:  Li-Liang Li; Ai-Min Xue; Bei-Xu Li; Yi-Wen Shen; Yu-Hua Li; Cheng-Liang Luo; Ming-Chang Zhang; Jie-Qing Jiang; Zu-De Xu; Jian-Hui Xie; Zi-Qin Zhao
Journal:  Breast Cancer Res       Date:  2014-05-30       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.